Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.

Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.

Item
http://www.wikidata.org/entity/Q34313870
Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics.Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinomaEnhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.Low-Dose Endothelial Monocyte-Activating Polypeptide-II Increases Blood-Tumor Barrier Permeability by Activating the RhoA/ROCK/PI3K Signaling Pathway.Low-Dose Endothelial Monocyte-Activating Polypeptide-II Induces Blood-Tumor Barrier Opening Via the cAMP/PKA/Rac1 Pathway.Roles of Serine/Threonine Phosphatases in Low-Dose Endothelial Monocyte-Activating Polypeptide-II-Induced Opening of Blood-Tumor Barrier.Role of cAMP-dependent protein kinase A activity in low-dose endothelial monocyte-activating polypeptide-II-induced opening of blood-tumor barrier.Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.Low-dose endothelial monocyte-activating polypeptide-ii increases permeability of blood-tumor barrier by caveolae-mediated transcellular pathway.Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma.
P2860

Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.

Item
http://www.wikidata.org/entity/Q34313870
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Evaluation of poly-mechanistic ...... response in pancreatic cancer.
@ast
Evaluation of poly-mechanistic ...... response in pancreatic cancer.
@en
Evaluation of poly-mechanistic ...... response in pancreatic cancer.
@nl
type
label
Evaluation of poly-mechanistic ...... response in pancreatic cancer.
@ast
Evaluation of poly-mechanistic ...... response in pancreatic cancer.
@en
Evaluation of poly-mechanistic ...... response in pancreatic cancer.
@nl
prefLabel
Evaluation of poly-mechanistic ...... response in pancreatic cancer.
@ast
Evaluation of poly-mechanistic ...... response in pancreatic cancer.
@en
Evaluation of poly-mechanistic ...... response in pancreatic cancer.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Evaluation of poly-mechanistic ...... response in pancreatic cancer.
@en
P2093
P2860
P304
P31
P356
10.1371/JOURNAL.PONE.0038477
P407
P433
P478
P577
P5875
P698
P921
P932